Drug Profile
Research programme: telomere capping inhibitors - Gemin X
Latest Information Update: 27 May 2011
Price :
$50
*
At a glance
- Originator Gemin X Biotechnologies
- Developer Exelgen; Gemin X Biotechnologies
- Class Small molecules
- Mechanism of Action Heterogeneous nuclear ribonucleoprotein group A B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Nov 2007 Tripos Discovery Research is now called Exelgen
- 10 Aug 2007 Lead compound series discovered
- 25 Jan 2006 Preclinical trials in Cancer in Canada (unspecified route)